Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC

Liver International 2026

View at publisher

Authors: Xin Ming Xiang, Yang Yu

DOI: 10.1111/liv.70512

Cited by: 1

References: 5

Abstract

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Cancer Immunotherapy and Biomarkers HER2/EGFR in Cancer Research CAR-T cell therapy research

References 5